KITE-363

Phase 2

Phase 2

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No catalyst events have been recorded for this drug yet.

Competitive Landscape

0 competitors in Relapsed and/or Refractory B-cell Lymphoma

Drug Information

Target Indication

Relapsed and/or Refractory B-cell Lymphoma

Clinical Trial

Last updated: 2/19/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Drug Science

Mechanism of action & safety profile

Developer

GILD

Gilead Sciences, Inc.

Related Pipeline

Head and Neck Squamous Cell Carcinoma

HIV Prevention

Myelodysplastic Syndrome

Rheumatoid Arthritis

Acquired Immunodeficiency Syndrome